Evidence map›Paper›PMID 41189746›Full record

ReviewFrontiers in neuroscience2025

DYRK1A in the physiology and pathology of the neuron-astrocyte axis.

Pablo Cisternas, Jiyoon Kim, Brandon Ashfeld, Jeremiah Zartman

Abstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pablo CisternasDepartment of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN, United States.
Jiyoon KimDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, United States.
Brandon AshfeldDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, United States.
Jeremiah ZartmanDepartment of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN, United States.

Funding

Regulation and function of multicellular calcium signaling in organ growth and regenerationR35GM156615 · NIGMS · UNIVERSITY OF NOTRE DAME · PI Jeremiah James Zartman · 2025 to 2026
$1.1M
NIGMS NIH HHS R35 GM156615
6 · The paper itself

Abstract

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a dosage-sensitive kinase with critical roles in the neuron-astrocyte axis. During brain development, DYRK1A ensures the proper number of differentiated neurons and astrocytes. In neurons, this DYRK1A regulates neuronal morphogenesis and synaptic transmission. However, its functions in astrocytes are not yet well defined, with limited evidence indicating roles in astrocyte reactivity and excitotoxicity. Due to trisomy 21, DYRK1A is overexpressed in individuals with Down syndrome (DS). This imbalance directly contributes to neuronal death and likely astrocyte pathology, accelerating the onset of Alzheimer's disease (AD) in this population. Notably, DYRK1A overexpression also correlates with neurodegeneration and AD progression in elderly euploid adults. This correlation positions DYRK1A as a potential bridge between DS and AD, mechanistically connecting gene overdosage and neuropathology in both conditions. However, research on DYRK1A pathophysiology has primarily centered on neurons, leaving astrocytes largely understudied. Considering the vital neuroprotective functions of astrocytes, broadening DYRK1A research to encompass these cells presents an opportunity to uncover novel mechanisms contributing to the neurodegenerative process in AD. In this review, we highlight the physiology and pathology of DYRK1A in the neuron-astrocyte axis, analyzing its roles in neurons and positing hypothetical functions in astrocytes, with particular emphasis on the contribution of DYRK1A's cell-specific overexpression to neurodegeneration and AD progression.

Indexed as

Alzheimer’s diseaseastrocyteDYRK1Agene dosageneuron

Identifiers

PMID41189746
PMCPMC12580109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.